Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

Vivos Therapeutics Inc (VVOS)

Vivos Therapeutics Inc (VVOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Vivos Therapeutics (NASDAQ: VVOS) Secures Strategic Alliances to Enhance Clear Aligner Offerings and Bolster Revenue Streams Spotlight Growth - Wed Oct 4, 2023

Vivos Therapeutics Announces Strategic Agreements with Ormco and On Demand Orthodontist Vivos Therapeutics, Inc. (NASDAQ: VVOS), a prominent medical device

VVOS : 3.22 (-22.03%)
Vivos Therapeutics Announces Multiple Regulatory Clearances in Australia for Its Entire Line of Oral Appliances Business Wire - Thu Jul 14, 2022

Vivos Therapeutics, Inc . (NASDAQ: VVOS) is pleased to announce that it has received multiple Class I clearances by the Therapeutic Goods Administration for multiple indications to include the treatment...

VVOS : 3.22 (-22.03%)
Vivos Therapeutics’ SLEEP 2022 Annual Meeting Presentation Highlights Retrospective Study Demonstrating Significant Improvement in Sleep Apnea Globe Newswire - Tue Jun 14, 2022

Study Recently Presented at the SLEEP 2022 Annual Meeting...

VVOS : 3.22 (-22.03%)
Vivos Therapeutics Schedules First Quarter 2022 Financial Results Conference Call Globe Newswire - Thu Apr 28, 2022

Call Scheduled for Monday, May 16, 2022 at 5:00 pm ET...

VVOS : 3.22 (-22.03%)
Vivos Therapeutics Opens Third U.S. Multidisciplinary Center to Treat Patients Suffering from Sleep Apnea with The Vivos Method Globe Newswire - Tue Apr 26, 2022

New Pneusomnia Center in Toluca Lake, Calif., Will Combine Medical and Dental Expertise to Provide Comprehensive Care for Complex Airway Issues...

VVOS : 3.22 (-22.03%)
Vivos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update Globe Newswire - Thu Mar 31, 2022

Fourth Quarter Revenue Increased 33% Year-Over-Year While Full Year Revenue Increased 29% Management to Host Conference Call Today at 5:00 pm ET ...

VVOS : 3.22 (-22.03%)
Vivos Therapeutics Schedules Fourth Quarter and Full Year 2021 Financial Results Conference Call Globe Newswire - Thu Mar 31, 2022

Call Scheduled for Today, Thursday, March 31, 2022 at 5:00 pm ET...

VVOS : 3.22 (-22.03%)
Fast Company Selects Vivos Therapeutics for 2022 “World’s Most Innovative Companies” List Globe Newswire - Tue Mar 8, 2022

Pioneer in Treating Dentofacial Abnormalities and / or Mild-to-Moderate Obstructive Sleep Apnea Ranks Among Top 10 Most Innovative Medical Device Companies...

VVOS : 3.22 (-22.03%)
Vivos Therapeutics to Participate in Upcoming Investor Conferences Globe Newswire - Wed Mar 2, 2022

HIGHLANDS RANCH, Colo., March 02, 2022 (GLOBE NEWSWIRE) -- Vivos Therapeutics, Inc. (“Vivos” or the “Company'') (NASDAQ: VVOS), a medical technology...

VVOS : 3.22 (-22.03%)
Vivos Therapeutics Files for US Patent on Proprietary New Clinical Protocols After Seeing Further Significant Improvement in Reduction of Key Sleep Apnea Metric Globe Newswire - Thu Jan 27, 2022

Vivos’ Continuous Clinical Improvement Program Yields Promising Data in AHI Score Reductions for Patients with Obstructive Sleep Apnea...

VVOS : 3.22 (-22.03%)

Barchart Exclusives

Stock Index Futures Inch Lower as Euphoria Over Fed Rate Cut Ebbs, FedEx Results Disappoint Barchart - 46 minutes ago
September S&P 500 E-Mini futures (ESU24) are down -0.17%, and September Nasdaq 100 E-Mini futures (NQU24) are down -0.35% this morning as disappointing earnings results from global economic bellwether FedEx dampened optimism surrounding the outlook for interest rates, while investors geared up for the so-called triple-witching event later in the day. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot